Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vascular Solutions Preparing For Duett Vascular Sealing Launch, Going Public

This article was originally published in The Gray Sheet

Executive Summary

Vascular Solutions says it will allocate roughly $12 mil. of its upcoming $40 mil. initial public offering to establish a direct U.S. sales force over the next year to market the Duett vascular sealing device, which currently awaits FDA approval.

You may also be interested in...



Datascope v. Vascular Solutions

Motion for summary judgement by Vascular Solutions is granted March 15, thereby dismissing all counts of the patent infringement complaint brought by Datascope in July 1999 in U.S. district court. Datascope's complaint alleged that the clinical studies of the Vascular Solutions Duett sealing device infringed patents held by Datascope. The summary judgement is subject to appeal. The Duett, Vascular Solutions' only product, is awaiting FDA approval (1"The Gray Sheet" Aug. 9, p. 14)

Datascope v. Vascular Solutions

Motion for summary judgement by Vascular Solutions is granted March 15, thereby dismissing all counts of the patent infringement complaint brought by Datascope in July 1999 in U.S. district court. Datascope's complaint alleged that the clinical studies of the Vascular Solutions Duett sealing device infringed patents held by Datascope. The summary judgement is subject to appeal. The Duett, Vascular Solutions' only product, is awaiting FDA approval (1"The Gray Sheet" Aug. 9, p. 14)

Vascular Solutions' Duett Reduces Time To Hemostasis - Final SEAL Data

Time to hemostasis during interventional procedures was "significantly and noticeably decreased" using Vascular Solutions' Duett femoral closure device compared to manual compression, Stephen Ellis, MD, Cleveland Clinic, told attendees of the American Heart Association's scientific sessions Nov. 9 in Atlanta.

Related Content

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel